139 related articles for article (PubMed ID: 12766611)
1. PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus.
Ricci R; Komminoth P; Bannwart F; Torhorst J; Wight E; Heitz PU; Caduff RF
Diagn Mol Pathol; 2003 Jun; 12(2):71-8. PubMed ID: 12766611
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
3. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
4. Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability.
Fujii H; Matsumoto T; Yoshida M; Furugen Y; Takagaki T; Iwabuchi K; Nakata Y; Takagi Y; Moriya T; Ohtsuji N; Ohtsuji M; Hirose S; Shirai T
Hum Pathol; 2002 Apr; 33(4):421-8. PubMed ID: 12055677
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
[TBL] [Abstract][Full Text] [Related]
6. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J
Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566
[TBL] [Abstract][Full Text] [Related]
7. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
[TBL] [Abstract][Full Text] [Related]
8. Correspondence re: W.M. Lin et al., loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin. Cancer Res., 4: 2577-2583, 1998.
Matias-Guiu X; Bussaglia E; Catasus L; Lagarda H; Gras E; Machin P; Prat J
Clin Cancer Res; 2000 Apr; 6(4):1598-600. PubMed ID: 10778994
[No Abstract] [Full Text] [Related]
9. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases.
Bussaglia E; del Rio E; Matias-Guiu X; Prat J
Hum Pathol; 2000 Mar; 31(3):312-7. PubMed ID: 10746673
[TBL] [Abstract][Full Text] [Related]
10. Common genetic changes between endometriosis and ovarian cancer.
Obata K; Hoshiai H
Gynecol Obstet Invest; 2000; 50 Suppl 1():39-43. PubMed ID: 11093060
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity and genomic instability in synchronous endometrioid tumors of the ovary and endometrium.
Shenson DL; Gallion HH; Powell DE; Pieretti M
Cancer; 1995 Aug; 76(4):650-7. PubMed ID: 8625160
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of synchronous uterine and ovarian endometrioid tumors.
Emmert-Buck MR; Chuaqui R; Zhuang Z; Nogales F; Liotta LA; Merino MJ
Int J Gynecol Pathol; 1997 Apr; 16(2):143-8. PubMed ID: 9100068
[TBL] [Abstract][Full Text] [Related]
13. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
Cao SN; Chang KH; Luthra R; Liu J
Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
[TBL] [Abstract][Full Text] [Related]
14. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
15. [An approach to early genetic alterations in precancerous cells].
Sato N; Nishida M; Noguchi M
Hum Cell; 2000 Sep; 13(3):103-8. PubMed ID: 11197771
[TBL] [Abstract][Full Text] [Related]
16. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.
Freihoff D; Kempe A; Beste B; Wappenschmidt B; Kreyer E; Hayashi Y; Meindl A; Krebs D; Wiestler OD; von Deimling A; Schmutzler RK
Br J Cancer; 1999 Feb; 79(5-6):754-8. PubMed ID: 10070865
[TBL] [Abstract][Full Text] [Related]
17. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
18. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
19. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
20. Allelic imbalance and mutations of the PTEN gene in ovarian cancer.
Saito M; Okamoto A; Kohno T; Takakura S; Shinozaki H; Isonishi S; Yasuhara T; Yoshimura T; Ohtake Y; Ochiai K; Yokota J; Tanaka T
Int J Cancer; 2000 Jan; 85(2):160-5. PubMed ID: 10629071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
